Triglyceride-production rates in patients with type-4 hypertriglyceridaemia

Area of Science:

• Metabolic Disorders
• Lipid Metabolism
• Pharmacology

Background:

• Hypertriglyceridemia is a significant risk factor for cardiovascular disease.
• Understanding triglyceride production and clearance is crucial for managing lipid disorders.
• Very-low-density lipoproteins (VLDL) are primary carriers of triglycerides in plasma.

Purpose of the Study:

• To investigate a novel method for assessing triglyceride production rates in humans.
• To evaluate the effect of protamine sulfate on plasma triglyceride clearance.
• To differentiate mechanisms of hypertriglyceridemia based on response to protamine sulfate.

Main Methods:

• A new method utilizing protamine sulfate to inhibit plasma triglyceride clearance was employed.
• Plasma triglyceride levels were measured over one hour following protamine sulfate administration.
• The study compared responses in healthy controls, patients with type IV hypertriglyceridemia, and those with severe hypertriglyceridemia.

Main Results:

• Protamine sulfate inhibited VLDL-triglyceride clearance by approximately 50%, leading to increased blood glycerides.
• Patients with type IV hypertriglyceridemia (fasting glycerides < 400 mg/dL) exhibited significantly higher plasma triglyceride increments compared to controls.
• Individuals with severe hypertriglyceridemia (fasting glycerides > 400 mg/dL) showed minimal change in plasma glycerides upon protamine sulfate administration, similar to controls.

Conclusions:

• Patients with type IV hypertriglyceridemia and fasting triglyceride levels below 400 mg/dL likely have increased triglyceride secretion rates.
• Severe hypertriglyceridemia may be associated with impaired triglyceride clearance, rather than overproduction.
• Protamine sulfate serves as a valuable tool for distinguishing between secretory and clearance defects in hypertriglyceridemia.